Related Experiment Video
Updated: Sep 16, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Nanotherapeutic System with Effective Microwave Sensitization and Pyroptosis Programming Enable Synergistic
Hao Deng1,2,3, Jinliang Huang1,2, Ning Gao1
1Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
Currently, the prognosis for patients with advanced bladder cancer remains poor, with only a minority being sensitive to immune checkpoint inhibitors. There is a need to develop additional treatment strategies. Microwave therapy, as a promising approach for some inoperable tumors, still faces challenges such as limited efficacy and high recurrence rates. Additionally, the cell damage and necrosis induced by conventional microwave treatment only act as weak immunostimulatory factors for antitumor immunity, failing to activate effective antitumor immune responses. Recent discoveries have shown that inducing pyroptosis can provide a good opportunity for enhancing systemic immune responses and alleviating immune suppression in cancer therapy. Here, we have developed Mn-ZrMOF@DAC, a microwave-sensitized nanoparticle loaded with the DNA methylation inhibitor decitabine. The Mn-ZrMOF@DAC can enhance the effect of microwave thermal therapy and generate reactive oxygen species under microwave irradiation, causing thermal and oxidative damage to cancer cells. Furthermore, there was an important up-regulation of the key pyroptosis protein GSDME, with a marked increase in pyroptotic cell numbers. In vivo experiments demonstrated that mice injected with Mn-ZrMOF@DAC nanoparticles followed by microwave radiation treatment exhibited potent antitumor effects and enhanced the efficacy of anti-PD-1 therapy. This therapy not only enhanced the efficacy of microwave treatment, exhibiting significant antitumor effects, but also activated antitumor immunity by inducing pyroptosis, thus enhancing the efficacy of immunotherapy for bladder cancer. It holds promise for providing new avenues in the treatment of bladder cancer.
Insights
This study introduces Mn-ZrMOF@DAC, a novel nanoparticle therapy that combines microwave treatment with decitabine to induce pyroptosis and enhance antitumor immunity for bladder cancer, improving immunotherapy efficacy.
Area of Science:
- Biomedical Engineering
- Cancer Therapy
- Immunology
Background:
- Advanced bladder cancer prognosis is poor, with limited response to current immunotherapies.
- Conventional microwave therapy has limitations in efficacy and immune stimulation.
- Pyroptosis induction is a promising strategy to enhance anti-tumor immunity.
Purpose of the Study:
- To develop a novel microwave-sensitized nanoparticle (Mn-ZrMOF@DAC) loaded with decitabine for bladder cancer treatment.
- To investigate the potential of this therapy to enhance microwave treatment efficacy and induce pyroptosis.
- To evaluate the combined effect of Mn-ZrMOF@DAC, microwave therapy, and anti-PD-1 immunotherapy in vivo.
Main Methods:
- Development of Mn-ZrMOF@DAC nanoparticles encapsulating decitabine.
- In vitro assessment of nanoparticle-mediated thermal and oxidative damage to cancer cells.
- Evaluation of pyroptosis induction via GSDME upregulation.
- In vivo studies in mice combining nanoparticle treatment, microwave radiation, and anti-PD-1 therapy.
Main Results:
- Mn-ZrMOF@DAC enhanced microwave thermal therapy, generating reactive oxygen species and causing cancer cell damage.
- The treatment significantly upregulated GSDME, a key pyroptosis protein, leading to increased pyroptotic cell death.
- In vivo experiments showed potent anti-tumor effects and enhanced efficacy of anti-PD-1 immunotherapy.
Conclusions:
- Mn-ZrMOF@DAC combined with microwave therapy effectively treats bladder cancer by inducing pyroptosis.
- This approach activates antitumor immunity, overcoming limitations of conventional microwave therapy.
- The developed therapy offers a promising strategy to enhance immunotherapy for advanced bladder cancer.

